Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03
Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MFB | Ann: Results of 2024 Annual Meeting | 16/08/24 | 0 | 100 | |||
|
|||||||
MFB | Ann: Annual Meeting Presentation | 16/08/24 | 0 | 109 | |||
|
|||||||
MFB | Ann: Notice of Meeting | 15/07/24 | 0 | 107 | |||
|
|||||||
MFB | Ann: Ongoing Disclosure Notice - Louise Newsome | 04/07/24 | 0 | 104 | |||
|
|||||||
MFB | Ann: Ongoing Disclosure Notices - Mark Winter | 04/07/24 | 0 | 92 | |||
|
|||||||
MFB | Ann: Issue of Ordinary Shares and Performance Rights | 04/07/24 | 0 | 102 | |||
|
|||||||
MFB | Ann: Closing Date for Director Nominations | 06/06/24 | 0 | 119 | |||
|
|||||||
MFB | Ann: Ongoing Disclosure Notice - Tony Carter | 05/06/24 | 0 | 108 | |||
|
See All Discussions